sargramostim tradename leukine recombinant granulocyte macrophage colonystimulating factor gmcsf functions immunostimulator sargramostim primarily used myeloid reconstitution autologous allogeneic bone marrow transplantation also used treat neutropenia induced chemotherapy treatment acute myeloid leukemia additionally used medical countermeasure treating people exposed sufficient radiation suppress bone marrow administered via intravenous infusion via subcutaneous sargramostim used people known hypersensitivity gmcsf yeastderived products component product concomitant use chemotherapy formulation benzyl alcohol toxic babies formulations used sargramostim tested pregnant women appears toxic fetuses data whether sargramostim expressed breast people experienced anaphylaxis given drug infusion reactions occurred well including edema capillary leak syndrome build fluid around lungs around irregular heart rhythms occurred especially people history problem suppresses white blood cells may promote tumor sargramostim version gmcsf normal role human biology causing progenitor cells differentiate neutrophils monocytes macrophages myeloidderived dendritic cells also activate mature granulocytes macrophages contribute differentiation megakaryocytic progenitors erythroid progenitor sargramostim recombinant version gmcsf glycoprotein made amino acids sargramostim mixture three versions gmcsf molecular weights daltons manufactured sequence human gmcsf first identified soon three recominbant human gmcsfs produced one bacteria one mammalian cells one immunex developed gmcsf manufactured yeast clinical trials sargramostim initiated year administered six people part compassionateuse protocol victims cesium irradiation goi√¢nia approved fda march trade name leukine acceleration white blood cell recovery following autologous bone marrow transplantation patients nonhodgkins lymphoma acute lymphocytic leukemia hodgkins november fda also approved sargramostim treatment fungal infections replenishment white blood cells following liquid formulation approved immunex acquired amgen part acquisition leukine spun berlex became bayer healthcare january bayer informed healthcare professionals market withdrawal current liquid formulation sargramostim liquid formulation withdrawn upward trend spontaneous reports adverse reactions including syncope fainting temporally correlated change made formulation around april include edetate disodium upward trend adverse reaction reporting rates observed use lyophilized original liquid formulation without edta returned market us may genzyme acquired rights leukine bayer including manufacturing facility seattle march label extended use countermeasure acute radiation february partner therapeutics inc acquired global rights develop manufacture commercialize leukine sargramostim httpsenwikipediaorgwikisargramostim